FDA says ‘no go’ to an Allergan women’s health med

Aug 22, 2018

The FDA has declined to approve a medication developed by Allergan to treat abnormal bleeding in women with uterine fibroids.

Regulators in Europe have already placed restrictions on the drug, Esmya, due to concerns it can cause rare but serious liver damage. The FDA cited “safety concerns regarding Esmya post-marketing reports outside the U.S.,” in its announcement that it is rejecting the drug all together. 

One analyst called the decision a “setback” for Allergan’s plan to sell off its women’s health and infectious disease division, but said that investors “will likely not be disturbed” by the news.

Uterine fibroids are a common condition that affect about 200,000 women in America each year.

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments